PL4243828T3 - Sposoby i kompozycje zawierające inhibitor KRasG12C i inhibitor VEGF do leczenia nowotworów litych - Google Patents

Sposoby i kompozycje zawierające inhibitor KRasG12C i inhibitor VEGF do leczenia nowotworów litych

Info

Publication number
PL4243828T3
PL4243828T3 PL21835890.1T PL21835890T PL4243828T3 PL 4243828 T3 PL4243828 T3 PL 4243828T3 PL 21835890 T PL21835890 T PL 21835890T PL 4243828 T3 PL4243828 T3 PL 4243828T3
Authority
PL
Poland
Prior art keywords
inhibitor
compositions
methods
solid tumors
krasg12c
Prior art date
Application number
PL21835890.1T
Other languages
English (en)
Inventor
Marie Evangelista
Mark Andrew MERCHANT
Jennifer Lee SCHUTZMAN
Ting-Kun Mark LIN
Stephanie Royer JOO
Sandhya Vinayak MANDLEKAR
Stuart G. LUTZKER
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of PL4243828T3 publication Critical patent/PL4243828T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL21835890.1T 2020-11-13 2021-11-11 Sposoby i kompozycje zawierające inhibitor KRasG12C i inhibitor VEGF do leczenia nowotworów litych PL4243828T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063113609P 2020-11-13 2020-11-13
PCT/US2021/058877 WO2022103905A1 (en) 2020-11-13 2021-11-11 Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors

Publications (1)

Publication Number Publication Date
PL4243828T3 true PL4243828T3 (pl) 2025-06-23

Family

ID=79185775

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21835890.1T PL4243828T3 (pl) 2020-11-13 2021-11-11 Sposoby i kompozycje zawierające inhibitor KRasG12C i inhibitor VEGF do leczenia nowotworów litych

Country Status (13)

Country Link
US (2) US12016862B2 (pl)
EP (1) EP4243828B1 (pl)
JP (1) JP2023550028A (pl)
KR (1) KR20230088781A (pl)
CN (1) CN116568326A (pl)
AU (2) AU2021377810B2 (pl)
CA (1) CA3201521A1 (pl)
ES (1) ES3032036T3 (pl)
IL (1) IL301293A (pl)
MX (1) MX2023005529A (pl)
PL (1) PL4243828T3 (pl)
TW (2) TW202535399A (pl)
WO (1) WO2022103905A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4243828T3 (pl) * 2020-11-13 2025-06-23 Genentech, Inc. Sposoby i kompozycje zawierające inhibitor KRasG12C i inhibitor VEGF do leczenia nowotworów litych
CA3255718A1 (en) 2022-04-06 2023-10-12 Genentech, Inc. Polytherapy involving GDC-6036 and GDC-0077 for cancer treatment

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
HU221343B1 (en) 1992-10-28 2002-09-28 Genentech Inc Use of anti-vegf antibodies for the treatment of cancer
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
KR100794454B1 (ko) 1997-04-07 2008-01-16 제넨테크, 인크. 항-ｖｅｇｆ 항체
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
KR20150008458A (ko) 2003-05-30 2015-01-22 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
WO2014009319A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
JOP20190272A1 (ar) * 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
US20210379095A1 (en) * 2018-02-12 2021-12-09 Array Biopharma Inc. Methods and Combination Therapy to Treat Biliary Tract Cancer
FI3735299T3 (fi) * 2018-11-09 2024-12-04 Hoffmann La Roche Fuusioituja rengasyhdisteitä
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
PL4243828T3 (pl) * 2020-11-13 2025-06-23 Genentech, Inc. Sposoby i kompozycje zawierające inhibitor KRasG12C i inhibitor VEGF do leczenia nowotworów litych

Also Published As

Publication number Publication date
TWI886356B (zh) 2025-06-11
MX2023005529A (es) 2023-05-25
CN116568326A (zh) 2023-08-08
JP2023550028A (ja) 2023-11-30
CA3201521A1 (en) 2022-05-19
AU2025201610A1 (en) 2025-03-27
US12016862B2 (en) 2024-06-25
AU2021377810B2 (en) 2025-01-02
KR20230088781A (ko) 2023-06-20
EP4243828B1 (en) 2025-04-02
AU2021377810A1 (en) 2023-05-11
US20220152030A1 (en) 2022-05-19
EP4243828A1 (en) 2023-09-20
TW202535399A (zh) 2025-09-16
US20240299392A1 (en) 2024-09-12
IL301293A (en) 2023-05-01
WO2022103905A1 (en) 2022-05-19
TW202224682A (zh) 2022-07-01
ES3032036T3 (en) 2025-07-15
US12409178B2 (en) 2025-09-09

Similar Documents

Publication Publication Date Title
IL272877A (en) SHP2 inhibitory compositions and methods for cancer treatment
IL277783A (en) SHP2 inhibitory compositions, methods for treating cancer and methods for identifying a subject with SHP2 mutations
IL286350A (en) Preparations and methods for the treatment of cancer
IL288914A (en) Preparations and methods for the treatment of cancer
PT4181920T (pt) Inibidor de kat6 e combinações para o tratamento do cancro da mama
SG11202011080QA (en) Methods and compositions for treating cancer
ZA202104870B (en) Methods and compositions for treating cancer
IL285886A (en) Preparations and methods for the treatment of laminopathy
IL287982A (en) Preparations and methods for the treatment of cancer
SG11202012435UA (en) Compositions and methods for treating cancer
IL285796A (en) Methods and preparations for the treatment of cancer
PL4243828T3 (pl) Sposoby i kompozycje zawierające inhibitor KRasG12C i inhibitor VEGF do leczenia nowotworów litych
IL287865A (en) Pde9 inhibitors for treating thalassemia
IL286153A (en) Methods and preparations for the treatment of cancer
IL315800A (en) Preparations and methods for the treatment of cancer
IL309120A (en) Methods and compositions for the treatment of cancer
EP3788078A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CHRONIC URTICARIA
IL319403A (en) Compositions and methods for treating advanced solid tumors
IL312846A (en) Methods and preparations for the treatment of cancer
IL309071A (en) Methods and compositions for the treatment of cancer
SG11202109032SA (en) Compounds for treating and preventing net associated complications
IL285036A (en) Methods and preparations for the treatment of cancer
KR102349013B9 (ko) 멜라토닌을 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
KR102479523B9 (ko) Cotl1 억제제를 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
IL321784A (en) Compositions and methods for treating alpha-synucleinopathies